lifestyle.realie.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Bicara Therapeutics Inc.
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
April 3, 2026
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 30, 2026
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
March 23, 2026
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
March 4, 2026
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 26, 2026
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
February 24, 2026
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
February 24, 2026
Bicara Therapeutics to Participate in Upcoming Investor Conferences
February 23, 2026
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
February 19, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 7, 2026